Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | SCN9A | Q15858 | 6/20 | 0.47 |
| ▸ | FAAH | O00519 | 4/20 | 0.46 |
| ▸ | MGLL | Q99685 | 3/20 | 0.46 |
| ▸ | LIPE | Q05469 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | SCN10A | Q9Y5Y9 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1009588 | 1.00 | MAPK1 (0.64) | MAPK1ALDH1A1POLBL3MBTL1HPGD | |
| SCHEMBL27072759 | 0.90 | MAPK1 (0.63) | MAPK1ALDH1A1POLBL3MBTL1HPGD | |
| SCHEMBL1012147 | 0.87 | MAPK1 (0.61) | MAPK1HPGDSCN9ALIPETHRB | |
| SCHEMBL14810517 | 0.86 | MAPK1 (0.51) | MAPK1HPGDSCN9ATHRBSCN10A | |
| SCHEMBL27233677 | 0.85 | MAPK1 (0.44) | MAPK1ALDH1A1POLBL3MBTL1RAB9A | |
| SCHEMBL1012278 | 0.85 | MAPK1 (0.50) | MAPK1L3MBTL1HPGDSCN9ATHRB | |
| SCHEMBL1011533 | 0.84 | MAPK1 (0.42) | MAPK1ALDH1A1POLBL3MBTL1RAB9A | |
| SCHEMBL27040222 | 0.84 | MAPK1 (0.59) | MAPK1ALDH1A1POLBL3MBTL1SCN9A | |
| SCHEMBL1011229 | 0.84 | FDFT1 (0.49) | MAPK1 | |
| SCHEMBL1011032 | 0.83 | MAPK1 (0.41) | MAPK1ALDH1A1POLBL3MBTL1THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4554674-A1 | BIARYL ETHER UREA COMPOUNDS AS FAAH INHIBITORS | Jazz Pharmaceuticals Ireland Limited (IE) | 2025-05-21 | — | — | EP | disclosed |
| US-20240024313-A1 | BIARYL ETHER UREA COMPOUNDS | Jazz Pharmaceuticals Therapeutics, Inc. | 2024-01-25 | — | — | US | disclosed |
| WO-2024013567-A1 | BIARYL ETHER UREA COMPOUNDS AS FAAH INHIBITORS | JAZZ PHARMACEUTICALS IRELAND LIMITED (IE) | 2024-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240024313-A1 | BIARYL ETHER UREA COMPOUNDS | FAAH, FAAH2, FAH | MAPK1 4121/4885ALDH1A1 309/4885POLB 1890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.